Danaher Corporation (DHR) income statement
NYSE · Healthcare · Medical - Diagnostics & Research · 59,000 employees · CEO Julie Sawyer Montgomery
- Price
- $232.23 -2.00%
- Market cap
- $163B
- Enterprise value
- $184B
- Last report
- Q3 '26 filed 2026-10-21
- Next report
- 2027-01-27 EPS est. $2.49
Danaher Corporation (DHR) reported revenue of $6.55B for Q3 '26 (+8.3% year on year), operating income of $1.25B (19.0% of revenue) and net income of $1.24B. Over the last four quarters revenue was $25.6B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.41B | $5.8B | $5.74B | $5.8B | $6.54B | $5.74B | $5.94B | $6.05B | $6.84B | $5.95B | $6.27B | $6.55B | |
| Cost of revenue | $2.63B | $2.31B | $2.32B | $2.4B | $2.65B | $2.23B | $1.98B | $2.53B | $2.87B | $2.36B | $2.65B | $2.72B | |
| Gross profit | $3.78B | $3.49B | $3.43B | $3.4B | $3.89B | $3.51B | $3.96B | $3.52B | $3.97B | $3.59B | $3.61B | $3.84B | |
| Research & development | $407M | $368M | $391M | $383M | $442M | $379M | $403M | $378M | $438M | $387M | $412M | $433M | |
| Sales & marketing | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2.07B | $0 | |
| General & administrative | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.86B | $0 | $0 | |
| Operating expenses | $2.37B | $2.18B | $2.26B | $2.44B | $2.14B | $2.24B | $2.76B | $2.37B | $2.46B | $2.25B | $2.48B | $2.59B | |
| Operating income | $1.41B | $1.31B | $1.17B | $958M | $1.75B | $1.27B | $1.19B | $1.15B | $1.5B | $1.34B | $1.13B | $1.25B | |
| Interest income | $117M | $60M | $39M | $4M | $14M | $6M | $8M | $3M | $13M | $27M | $61M | $31M | |
| Interest expense | $85M | $65M | $65M | $87M | $61M | $72M | $71M | $67M | $55M | $63M | -$107M | $135M | |
| Other non-operating income (gains on investments, FX ...) | $97M | -$24M | $20M | -$106M | $370M | $73M | $466M | $11M | $74M | $46M | -$58M | -$22M | |
| Total non-operating income | -$182M | -$41M | -$85M | $19M | -$431M | -$145M | -$537M | -$78M | -$129M | -$109M | -$49M | -$113M | |
| Income before tax | $1.23B | $1.27B | $1.08B | $977M | $1.32B | $1.13B | $655M | $1.08B | $1.37B | $1.24B | $1.08B | $1.13B | |
| Income tax | $111M | $183M | $176M | $159M | $229M | $175M | $100M | $168M | $176M | $206M | $208M | -$103M | |
| Net income | $1.08B | $1.09B | $907M | $818M | $1.09B | $954M | $555M | $908M | $1.2B | $1.03B | $870M | $1.24B | |
| EPS (basic) | $1.46 | $1.47 | $1.23 | $1.13 | $1.50 | $1.33 | $0.77 | $1.28 | $1.69 | $1.45 | $1.23 | $1.75 | |
| EPS (diluted) | $1.45 | $1.45 | $1.22 | $1.12 | $1.49 | $1.32 | $0.77 | $1.27 | $1.68 | $1.45 | $1.23 | $1.75 | |
| Shares (basic, weighted) | 740M | 741M | 738M | 723M | 731M | 716M | 717M | 711M | 707M | 708M | 705M | 704M | |
| Shares (diluted, weighted) | 746M | 749M | 742M | 729M | 737M | 721M | 719M | 714M | 711M | 711M | 708M | 707M | |
| Depreciation & amortization | $493M | $586M | $580M | $591M | $595M | $591M | $611M | $622M | $623M | $627M | $659M | $0 | |
| EBITDA | $1.81B | $1.92B | $1.73B | $1.66B | $1.97B | $1.79B | $1.34B | $1.77B | $2.05B | $1.93B | $1.84B | $1.27B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.9B | $18.3B | $17B | $17.9B | $22.3B | $29.5B | $26.6B | $23.9B | $23.9B | $24.6B | |
| Cost of revenue | $7.5B | $8.1B | $7.54B | $7.93B | $9.81B | $11.5B | $10.5B | $9.86B | $9.67B | $9.6B | |
| Gross profit | $9.38B | $10.2B | $9.51B | $9.98B | $12.5B | $18B | $16.2B | $14B | $14.2B | $15B | |
| Research & development | $975M | $1.13B | $1.06B | $1.13B | $1.35B | $1.74B | $1.53B | $1.5B | $1.58B | $1.6B | |
| Operating expenses | $6.4B | $7.08B | $6.44B | $6.62B | $8.16B | $9.9B | $8.65B | $8.76B | $9.02B | $9.83B | |
| Operating income | $2.99B | $3.15B | $3.07B | $3.36B | $4.31B | $8.05B | $7.54B | $5.28B | $5.18B | $5.14B | |
| Interest income | $200K | $7.5M | $9.2M | $139M | $71M | $11M | $41M | $303M | $117M | $30M | |
| Interest expense | $184M | $163M | $137M | $109M | $273M | $241M | $207M | $289M | $278M | $265M | |
| Other non-operating income (gains on investments, FX ...) | $192M | $48M | -$28.7M | -$51.5M | -$456M | $211M | $183M | -$54M | $260M | $639M | |
| Total non-operating income | -$376M | -$211M | -$108M | -$57.1M | $183M | -$452M | -$390M | -$235M | -$538M | -$904M | |
| Income before tax | $2.61B | $2.94B | $2.96B | $3.31B | $4.5B | $7.6B | $7.15B | $5.04B | $4.65B | $4.23B | |
| Income tax | $458M | $469M | $556M | $873M | $849M | $1.25B | $818M | $823M | $747M | $619M | |
| Net income | $2.55B | $2.49B | $2.65B | $2.56B | $3.65B | $6.43B | $7.21B | $4.76B | $3.9B | $3.61B | |
| EPS (basic) | $3.69 | $3.58 | $3.78 | $3.48 | $4.97 | $8.77 | $9.80 | $6.44 | $5.33 | $5.07 | |
| EPS (diluted) | $3.65 | $3.53 | $3.73 | $3.43 | $4.89 | $8.61 | $9.64 | $6.38 | $5.29 | $5.04 | |
| Shares (basic, weighted) | 691M | 696M | 701M | 715M | 706M | 715M | 725M | 737M | 731M | 707M | |
| Shares (diluted, weighted) | 700M | 706M | 710M | 726M | 719M | 737M | 737M | 743M | 737M | 711M | |
| Depreciation & amortization | $1.13B | $1.24B | $1.18B | $1.19B | $1.78B | $2.17B | $2.13B | $2.17B | $2.35B | $2.45B | |
| EBITDA | $3.92B | $4.34B | $4.28B | $4.6B | $6.54B | $10B | $9.49B | $7.5B | $7.28B | $6.95B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-25, 10-Q 2026-06-26, 10-Q 2026-03-27, 10-K 2025-12-31, 10-Q 2025-09-26, 10-Q 2025-06-27, 10-Q 2025-03-28, 10-K 2024-12-31, 10-Q 2024-09-27
Data as of 2026-11-01